Zepbound Cost Without Insurance — LillyDirect & Alternatives

Normalized pricing table

Every row is sorted by the recurring monthly figure used in the captured offer. Required memberships are added where known. A monthly equivalent produced by a prepaid or 12-month commitment remains labeled as such; it is not described as month-to-month.

Providers not ranked in this medication-specific table

The providers below publish broad program ranges that mix medications, formats, starter prices, dose tiers or insurance pathways. Their lowest headline amount is not treated as the price of tirzepatide unless a current medication-specific recurring total can be normalized.

How Peptides Editorial normalizes price

Microdose, standard dose and brand medication are different categories

Microdose is not a standardized FDA category. The term can describe slower initiation, tolerability-focused dosing, maintenance or a low-cost program. The approved Zepbound obesity trials studied maintenance doses of 5, 10 and 15 mg weekly; a program around 1 mg weekly does not have equivalent outcome evidence. Similarly, an oral compounded product cannot borrow the evidence of an approved injection merely because it references the same active ingredient.

Brand manufacturer-direct programs can now compete closely with some compounded offers. Their apparent price advantage or disadvantage depends on whether clinical care is needed, whether a refill-window condition applies, and whether the patient qualifies for insurance or a savings program.

Decision guide

• Editor’s pick for an all-in program: NexLife, when its 12-month plan fits ($139 tirzepatide, $119 semaglutide). It is not the lowest price we track.
• Month to month: Eden ($129 tirzepatide, $99 semaglutide, no membership) has the lowest standing rate in our table; Mochi prices by dose plus a $79 membership.
• FDA-approved medication without telehealth care: manufacturer-direct LillyDirect or NovoCare pathways.
• Insurance-first care: evaluate prior-authorization support, visit charges and the plan formulary rather than cash prices alone.
• Microdose: compare actual milligrams, clinical goal and commitment—not the word “microdose.”

Frequently asked questions

Sources and update rule

Primary manufacturer and provider pages document price and terms; FDA labels and peer-reviewed trials document clinical claims. Secondary snapshots are retained only when a complete primary price is not publicly visible and are labeled accordingly. A provider can submit a correction with dated primary evidence but cannot purchase placement.

The real tirzepatide cost hierarchy

For a patient specifically seeking tirzepatide, three categories should be compared separately. A microdose program may have the smallest monthly number but uses a lower treatment intensity. A standard compounded program may include clinical care and shipping in one fee. Manufacturer-direct Zepbound is an FDA-approved product but generally excludes the telehealth clinician who evaluates and manages treatment.

NexLife’s $139 standard and $147 microdose figures require a 12-month plan; month to month they are $169 and $189. Enhance.MD’s $169 figure is a 1 mg/week microdose offer on a 12-month plan. Mochi now prices by dose: $90 (2.2 mg) to $199 (16.6 mg) for the medication plus a $79 monthly membership, or $169 to $278 a month in total. Eden now charges a flat $129 a month for tirzepatide at every dose, with no membership fee. LillyDirect lists Zepbound at $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5–15 mg under the timely-refill journey offer.

The 45-day refill condition

The $449 LillyDirect journey price for higher Zepbound doses depends on refilling within the stated 45-day period. A patient should count from delivery, allow processing time and confirm the current terms; the condition can materially affect annual cost. Manufacturer-direct pricing is medication-only, so a separate prescribing pathway may be needed.

Why Mounjaro is usually a poor cash-pay weight-loss comparison

Mounjaro and Zepbound contain tirzepatide but carry different approved indications. For a self-pay obesity patient, Zepbound’s manufacturer-direct pathway is generally the relevant brand comparison. Mounjaro may be financially sensible when insurance covers it for type 2 diabetes; a high retail cash price should not be treated as the unavoidable cost of tirzepatide.

Annual-cost examples

Annual arithmetic is illustrative. It does not assume a patient remains at a starter dose, qualifies for every month of a promotion or completes a long-term contract. The checkout agreement controls.

Regulatory and continuity cost

A lower compounded price can carry non-price tradeoffs: the product lacks FDA premarket approval, the pharmacy or concentration can change, and broad shortage-based copying has ended. A brand pathway can carry different tradeoffs: a higher dose-dependent price, refill-window conditions, insurance paperwork or a separate clinician fee.

Continuity should be budgeted as well. Ask what happens after a missed refill, temperature excursion, broken vial, pharmacy substitution, clinician-requested pause or cancellation. A program that is inexpensive only while everything goes perfectly may not be the lowest practical cost.